A strong internal promoter drives massive expression of YEATS-domain devoid MLLT3 transcripts in HSC and most lethal AML

Chloé Bessière; Ahmed Zamani; Romain Pfeifer; Sandra Dailhau; Camille Marchet; Benoit Guibert; Anthony Boureux; Raïssa Silva Da Silva; Nicolas Gilbert; Thérèse Commes; Fabienne Meggetto; Christian Touriol; Christian Récher; Marina Bousquet; Stéphane Pyronnet

doi:10.1002/cac2.12650

Cancer Communications ›› 2025, Vol. 45 ›› Issue (3) : 380 -385. DOI: 10.1002/cac2.12650

LETTER TO THE JOURNAL

A strong internal promoter drives massive expression of YEATS-domain devoid MLLT3 transcripts in HSC and most lethal AML

Author information +

History +

PDF

Cite this article

Download citation ▾

Chloé Bessière, Ahmed Zamani, Romain Pfeifer, Sandra Dailhau, Camille Marchet, Benoit Guibert, Anthony Boureux, Raïssa Silva Da Silva, Nicolas Gilbert, Thérèse Commes, Fabienne Meggetto, Christian Touriol, Christian Récher, Marina Bousquet, Stéphane Pyronnet. A strong internal promoter drives massive expression of YEATS-domain devoid MLLT3 transcripts in HSC and most lethal AML. Cancer Communications, 2025, 45(3): 380-385 DOI:10.1002/cac2.12650

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Li Y, Wen H, Xi Y, Tanaka K, Wang H, Peng D, et al. AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. Cell. 2014; 159: 558–571.

[2]	Li Y, Sabari BR, Panchenko T, Wen H, Zhao D, Guan H, et al. Molecular coupling of histone crotonylation and active transcription by AF9 YEATS domain. Mol Cell. 2016; 62: 181-193.

[3]	Kabra A, Bushweller J. The intrinsically disordered proteins MLLT3 (AF9) and MLLT1 (ENL) – multimodal transcriptional switches with roles in normal hematopoiesis, MLL fusion leukemia, and kidney cancer. J Mol Biol. 2022; 434: 167117.

[4]	Calvanese V, Nguyen AT, Bolan TJ, Vavilina A, Su T, Lee LK, et al. MLLT3 governs human haematopoietic stem-cell self-renewal and engraftment. Nature. 2019; 576: 281–286.

[5]	Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Gröger D, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023; 37(5): 988–1005.

[6]	Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell. 2002; 10: 1107–1117.

[7]	De Clara E, Gourvest M, Ma H, Vergez F, Tosolini M, Dejean S, et al. Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients. Haematologica. 2017; 102: 1718–1726.

[8]	Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018; 562: 526–531.

[9]	Alard A, Marboeuf C, Fabre B, Jean C, Martineau Y, Lopez F, et al. Differential regulation of the three eukaryotic mRNA translation Initiation factor (eIF) 4Gs by the proteasome. Front Genet. 2019; 10: 254.

[10]	Corre E, Soum C, Pfeifer R, Bessière C, Dailhau S, Marbœuf C, et al. Differential prognostic values of the three AKT isoforms in acute myeloid leukemia. Sci Rep. 2024; 14: 7070.